Introduction
Interferon (IFN)-γ, a cytokine produced by T and natural killer (NK) cells, plays an essential role in cell-mediated immunity, and it contributes to the control of the expansion of many normal and neoplastic cell types. 1 It exerts its biological activities by interacting with its specific cell surface receptor (IFN-γR), which consists of two IFN-γR1 binding chains and two IFN-γR2 signal transducing chains. 2 The binding of IFN-γ to its receptor complex activates the Janus kinase (JAK)/Signal Transducer and Activator of Transcription (STAT) signal transduction pathway [3] [4] [5] and induces the transcription of numerous sets of IFN-γ-inducible genes, 6 many of which with apoptotic activity. [7] [8] [9] [10] [11] However, IFN-γ does not always cause apoptosis or block proliferation. T lymphocytes that undergo Th1 polarization or malignant transformation become resistant to the antiproliferative/apoptotic effects of the IFN-γ/STAT1 pathway. [12] [13] [14] This refractoriness is mainly due to IFN-γR2 downregulation, [12] [13] [14] [15] [16] [17] due to ligand-independent internalization within clathrincoated pits. [18] [19] [20] By inducing IFN-γR2 internalization, both Insulin-like Growth Factor (IGF)-1 and iron are critical factors in limiting the IFN-γ/STAT1 pathway in T lymphocytes. [20] [21] [22] Since IGF-1 induces cell-membrane accumulation of the Transferrin Receptor (TfR), 23 which plays an obligatory role in the iron-induced IFN-γR2 internalization. 22 , blockade of IGF-1 signaling in T cells could perhaps hinder their intracellular IFN-γR2 trafficking and reinstate their sensitivity to IFN-γ/STAT1 apoptotic signaling.
IGF-1 is a growth factor mainly produced by the liver that plays an important role in the promotion of mitogenesis, transformation and protection from apoptosis of many cell types. [24] [25] [26] It acts by binding to IGF-1R, a type II tyrosine kinase receptor composed of two extracellular α subunits that bind ligand, and two trans-membrane catalytic β subunits. 24, 27, 28 Upon ligand Preclinical studies have demonstrated that genetic or pharmacological inhibition of IGF-1 signaling reverses the neoplastic phenotype of many tumor cells. 30 The effects of specific blockade of IGF-1 signaling on malignant T cells, however, has not been investigated. These data could be used in the elaboration of new therapeutic approaches based on IFN-γ administration to overcome the resistance of malignant cells to the inhibitory effect of IGF-1 signaling blockade.
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Material and methods

Media
The culture media were RPMI 1640 (BioWhittaker Inc., Walkersville, MD) containing gentamycin (Schering-Plough, Milan, Italy) with or without 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA), designated complete medium and serum-free medium, respectively. All in vitro cultures were maintained at 37° C in a 5% CO 2 humidified atmosphere.
Malignant cells
Human ST4 T cells were derived from a childhood convoluted-type T cell lymphoma, while PF382
were derived from a T-acute lymphoblastic leukemia. They were stabilized both in vitro and in nu/nu mice starting from bioptic material. Jurkat (ATCC, CRL8161) T cells were derived from an acute lymphoblastic leukemia. All these malignant T cell lines are incapable of producing IFN-γ.
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Construction of retroviral vectors, production of retroviral particles and viral transduction
A cDNA fragment encoding the first 516 aminoacids (486 after the removal of the signal peptide) of the human IGF-1R -called 486/STOP, created by introduction of a point mutation in codon 486
(not including the signal peptide) that results in a premature stop signal and consequently in the production of a truncated soluble receptor 31 -and a cDNA fragment encoding the full-length IGF-1R were excised from the plasmid pCvn (kindly donated by Dr. R. Baserga 
Western blot analysis
To evaluate protein amount of the wild-type and mutant forms of IGF-1Rα, 5 x 10 6 cells were lysed on ice with cold lysis buffer as previously described 21 At the end of this period, tumor-free mice were classified as survivors. Latency time was considered as the period (in days) between challenge and the growth of neoplastic masses to a mean diameter of 3 mm. Mice were killed for human reasons when the tumor exceeded 12 mm mean diameter.
Statistical analysis
Pearson's t-test (GraphPad Prism 3, GraphPad Software, Inc., San Diego, CA) was used to analyze the effect of IFN-γ on the in vivo growth of ST4 cells with P less than .05 as the significance cutoff. 
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The IGF-1-dependent proliferative response of ST4-E, ST4-WT and ST4-DN cells was also analyzed. As serum deprivation is a simple and convenient way to deplete IGF-1 from cells in culture, cells were cultured in the absence of serum and in the presence of scalar doses of IGF-1 for 72 hours. While ST4-E and ST4-WT proliferated in a dose-dependent manner in response to IGF-1, this response was completely abolished in ST4-DN cells ( Figure 1D ).
These data indicate that the expression of IGF-1R DN in ST4 cells completely abrogates IGF-1-dependent Akt and MAPK activation and proliferation.
Effect of IGF-1R DN on IFN-γR2 internalization
We had previously demonstrated that IGF-1 limits the IFN-γ/STAT1 pathway by delivering a signal for IFN-γR2 internalization. 21 Since IFN-γR2 is mainly endocytosed in malignant T cells, 8 we 
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In certain conditions IFN-γ induces STAT3 phosphorylation as well, leading to proliferative effects. 7 We used Western blot analysis with a specific Ab to determine the time course of STAT3 phosphorylation in ST4-E, ST4-WT and ST4-DN cells treated with IFN-γ. IFN-γ did not induce STAT3 phosphorylation in any cell type, though it was observed in ST4-E, ST4-WT and ST4-DN treated for 15 minutes with 2 ng/mL of IFN-α (positive control, Figure 3C ).
These data together with the results on IFN-γR2 expression indicate that IGF-1R DN restores the IFN-γ/STAT1 signaling and leads to induction of IRF-1.
IGF-1R DN reinstates malignant T cell sensitivity to IFN-γ-dependent apoptosis
As IRF-1 induces the expression of FasL, which triggers the Fas-dependent cell death program, 40 the effects of IFN-γ on Fas and FasL surface expression in ST4-E, ST4-WT and ST4-DN were investigated.
Cells were treated for 24 hours ± IFN-γ, then Fas and FasL surface expression was evaluated using specific mAbs. Flow cytometry showed that IFN-γ did not enhance the constitutive high expression of Fas in ST4-E and ST4-WT, but slightly enhanced that in ST4-DN ( Figure 4A) . Moreover, the low or absent amount of FasL membrane expression in ST4-E and ST4-WT was not increased by IFN-γ, whereas it strongly enhanced this expression in ST4-DN ( Figure 4B ).
These data suggested that IFN-γ blocks ST4-DN cell proliferation by up-regulating Fas and
FasL expression. This was evaluated by culturing ST4-E, ST4-WT and ST4-DN in complete medium in the presence of scalar doses of IFN-γ and evaluating their proliferation after 72 hours.
ST4-E and ST4-WT displayed a slight dose-dependent increase of proliferation in response to IFN-γ, indicating that they were resistant to its anti-proliferative effect, whereas a dose-dependent inhibition was induced in ST4-DN ( Figure 4C ). 
Effect of IGF-1R DN on the in vivo growth of malignant T cells
The ability of IGF-1R DN to restore IFN-γ-dependent growth inhibition of ST4 cells in a SCID mouse model was evaluated. ST4-WT and ST4-DN cells were injected subcutaneously into SCID mice that then were treated with IFN-γ or vehicle alone for 5 days. Twenty-four hours before tumor cell challenge, and then weekly, mice were further immunosuppressed with anti-asialo GM1 rabbit antiserum to eliminate residual NK activity. 41 Growth of ST4-WT cells (evaluated as mean diameter of the tumor generated in the site of inoculum) was not significantly inhibited by IFN-γ, whereas Crosstalk with TfR, whose trafficking is also clathrin-dependent, 46 is probably involved. We have previously reported that in T cells iron, through TfR, induces internalization of IFN-γR2. 22 For
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Interestingly, IGF-1 enhances iron uptake by inducing an increase of TfR at the cell surface. 23 In Many data show that IGF-1 and IGF-1R are good targets for cancer therapy, as they help to establish and maintain the transformed phenotype. [24] [25] [26] 30 Inhibition of IGF-1R causes apoptosis and growth arrest of many cancer cells cultured in vitro or xenotransplanted into immunodeficient mice. 52 Several ways of blocking IGF-1R have been experimented, including antisense oligonucleotides, 53 blocking Abs, [54] [55] [56] peptides that mimic IGF-1, 57 truncated dominant negative forms of IGF-1R, 27, 31, 34, 58, 59 small molecules that specifically inhibit IGF-1R kinase activity 42, 60, 61 and specific peptide aptamers, 52 in a wide range of tumors, including hematological tumors, such as multiple myeloma, myeloid leukemias and B-cell lymphomas. [60] [61] [62] 
